Verona Pharma plc (VRNA)

Verona Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0	0.46	40	0	0
Revenue Growth (YoY)	-	-98.86%	-	-	-
Cost of Revenue	0	0.35	0	0	0
Gross Profit	0	0.11	40	0	0
Selling, General & Admin	50.35	26.58	33.91	29.77	9.99
Research & Development	17.22	49.28	79.41	44.51	42.42
Operating Expenses	67.57	75.86	113.31	74.28	52.4
Operating Income	-67.57	-75.75	-73.31	-74.28	-52.4
Interest Expense / Income	2.06	0.52	0.34	0.04	0
Other Expense / Income	-15.73	-7.82	-18.07	-9.31	-11.91
Pretax Income	-53.9	-68.45	-55.59	-65	-40.49
Income Tax	0.47	0.25	-0.02	0.15	0.07
Net Income	-54.37	-68.7	-55.57	-65.15	-40.56
Shares Outstanding (Basic)	634	529	480	345	105
Shares Outstanding (Diluted)	634	529	-	-	-
Shares Change	19.86%	10.20%	39.23%	227.37%	0.29%
EPS (Basic)	-0.72	-1.04	-0.96	-2.00	-3.12
EPS (Diluted)	-0.72	-1.04	-0.96	-2.00	-3.12
Free Cash Flow	-50.22	-59.89	-33.27	-45.16	-42.92
Free Cash Flow Per Share	-0.63	-0.91	-0.55	-1.05	-3.26
Gross Margin	-	24.45%	100.00%	-	-
Operating Margin	-	-16539.30%	-183.28%	-	-
Profit Margin	-	-15000.22%	-138.92%	-	-
Free Cash Flow Margin	-	-13076.64%	-83.17%	-	-
EBITDA	-51.16	-67.29	-54.62	-64.34	-39.98
EBITDA Margin	-	-14692.36%	-136.55%	-	-
Depreciation & Amortization	0.68	0.64	0.63	0.62	0.51
EBIT	-51.84	-67.93	-55.25	-64.97	-40.49
EBIT Margin	-	-14831.22%	-138.12%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).